{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["immune cell", "osteosarcoma", "prognosis", "riskscore", "signature"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "36189307", "DateCompleted": {"Year": "2022", "Month": "10", "Day": "04"}, "DateRevised": {"Year": "2022", "Month": "10", "Day": "05"}, "Article": {"ArticleDate": [{"Year": "2022", "Month": "09", "Day": "14"}], "Language": ["eng"], "ELocationID": ["1017120", "10.3389/fimmu.2022.1017120"], "Journal": {"ISSN": "1664-3224", "JournalIssue": {"Volume": "13", "PubDate": {"Year": "2022"}}, "Title": "Frontiers in immunology", "ISOAbbreviation": "Front Immunol"}, "ArticleTitle": "A novel immune cell signature for predicting osteosarcoma prognosis and guiding therapy.", "Pagination": {"StartPage": "1017120", "MedlinePgn": "1017120"}, "Abstract": {"AbstractText": ["Dysregulation of immune cell infiltration in the tumor microenvironment contributes to the progression of osteosarcoma (OS). In the present study, we explored genes related to immune cell infiltration and constructed a risk model to predict the prognosis of and guide therapeutic strategies for OS. The gene expression profile of OS was obtained from TARGET and Gene Expression Omnibus, which were set as the discovery and verification cohorts. CIBERSORT and Kaplan survival analyses were used to analyze the effects of immune cells on the overall survival rates of OS in the discovery cohort. Differentially expressed gene (DEG) analysis and protein-protein interaction (PPI) networks were used to analyze genes associated with immune cell infiltration. Cox regression analysis was used to select key genes to construct a risk model that classified OS tissues into high- and low-risk groups. The prognostic value of the risk model for survival and metastasis was analyzed by Kaplan-Meier survival analyses, receiver operating characteristic curves, and immunohistochemical experiments. Immunological characteristics and response effects of immune checkpoint blockade (ICB) therapy in OS tissues were analyzed using the ESTIMATE and Tumor Immune Dysfunction and Exclusion algorithms, while sensitivity for both targeted and chemotherapy drugs was analyzed using the OncoPredict algorithm. It was demonstrated that the high infiltration of resting dendritic cells in OS tissues was associated with poor prognosis. A total of 225 DEGs were found between the high- and low-infiltration groups of OS tissues, while 94 genes interacted with others. Through COX analyses, among these 94 genes, four genes (including AOC3, CDK6, COL22A1, and RNASE6) were used to construct a risk model. This risk model showed a remarkable prognostic value for survival rates and metastasis in both the discovery and verification cohorts. Even though a high microsatellite instability score was observed in the high-risk group, the ICB response in the high-risk group was poor. Furthermore, using OncoPredict, we found that the high-risk group OS tissues were resistant to seven drugs and sensitive to 25 drugs. Therefore, our study indicates that the resting dendritic cell signature constructed by AOC3, CDK6, COL22A1, and RNASE6 may contribute to predicting osteosarcoma prognosis and thus therapy guidance."], "CopyrightInformation": "Copyright \u00a9 2022 Pan, Pan, Zeng, Lei, Yang, Yang, Hu, Chen and Tian."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Basic Medicine, Guizhou Medical University, Guiyang, China."}], "LastName": "Pan", "ForeName": "Runsang", "Initials": "R"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Bone and Joint Surgery, Guizhou Orthopedics Hospital, Guiyang, China."}], "LastName": "Pan", "ForeName": "Feng", "Initials": "F"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Basic Medicine, Guizhou Medical University, Guiyang, China."}, {"Identifier": [], "Affiliation": "Transformation Engineering Research Center of Chronic Disease Diagnosis and Treatment, Guizhou Medical University, Guiyang, China."}], "LastName": "Zeng", "ForeName": "Zhirui", "Initials": "Z"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Basic Medicine, Guizhou Medical University, Guiyang, China."}, {"Identifier": [], "Affiliation": "Transformation Engineering Research Center of Chronic Disease Diagnosis and Treatment, Guizhou Medical University, Guiyang, China."}], "LastName": "Lei", "ForeName": "Shan", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Basic Medicine, Guizhou Medical University, Guiyang, China."}, {"Identifier": [], "Affiliation": "Transformation Engineering Research Center of Chronic Disease Diagnosis and Treatment, Guizhou Medical University, Guiyang, China."}], "LastName": "Yang", "ForeName": "Yan", "Initials": "Y"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pathology, Affiliated Hospital of Guizhou Medical University, Guiyang, China."}], "LastName": "Yang", "ForeName": "Yushi", "Initials": "Y"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang, China."}, {"Identifier": [], "Affiliation": "Guizhou Provincial Engineering Technology Research Center for Chemical Drug R&D, Guizhou Medical University, Guiyang, China."}], "LastName": "Hu", "ForeName": "Chujiao", "Initials": "C"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Orthopedics, Guiyang Maternal and Child Health-Care Hospital, Guiyang, China."}], "LastName": "Chen", "ForeName": "Houping", "Initials": "H"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Basic Medicine, Guizhou Medical University, Guiyang, China."}, {"Identifier": [], "Affiliation": "Department of Orthopedics, The Affiliated Hospital of Guizhou Medical University, Guiyang, China."}], "LastName": "Tian", "ForeName": "Xiaobin", "Initials": "X"}], "PublicationTypeList": ["Journal Article", "Research Support, Non-U.S. Gov't"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Front Immunol", "NlmUniqueID": "101560960", "ISSNLinking": "1664-3224"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Immune Checkpoint Inhibitors"}], "MeshHeadingList": [{"QualifierName": ["genetics", "therapy"], "DescriptorName": "Bone Neoplasms"}, {"QualifierName": [], "DescriptorName": "Gene Expression Profiling"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["therapeutic use"], "DescriptorName": "Immune Checkpoint Inhibitors"}, {"QualifierName": ["genetics", "pathology", "therapy"], "DescriptorName": "Osteosarcoma"}, {"QualifierName": [], "DescriptorName": "Prognosis"}, {"QualifierName": ["genetics"], "DescriptorName": "Tumor Microenvironment"}], "CoiStatement": "The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Ritter J, Bielack SS. Osteosarcoma. Ann Oncol (2010) 21(Suppl 7):vii320\u20135. doi:\u00a010.1093/annonc/mdq276", "ArticleIdList": ["10.1093/annonc/mdq276", "20943636"]}, {"Citation": "Benjamin RS. Adjuvant and neoadjuvant chemotherapy for osteosarcoma: A historical perspective. Adv Exp Med Biol (2020) 1257:1\u201310. doi:\u00a010.1007/978-3-030-43032-0_1", "ArticleIdList": ["10.1007/978-3-030-43032-0_1", "32483726"]}, {"Citation": "Ferrari S, Serra M. An update on chemotherapy for osteosarcoma. Expert Opin Pharmacother (2015) 16:2727\u201336. doi:\u00a010.1517/14656566.2015.1102226", "ArticleIdList": ["10.1517/14656566.2015.1102226", "26512909"]}, {"Citation": "Cascini C, Chiodoni C. The immune landscape of osteosarcoma: Implications for prognosis and treatment response. Cells (2021) 10:1668. doi:\u00a010.3390/cells10071668", "ArticleIdList": ["10.3390/cells10071668", "PMC8304628", "34359840"]}, {"Citation": "Huang Q, Liang X, Ren T, Huang Y, Zhang H, Yu Y, et al. . The role of tumor-associated macrophages in osteosarcoma progression - therapeutic implications. Cell Oncol (Dordr) (2021) 44:525\u201339. doi:\u00a010.1007/s13402-021-00598-w", "ArticleIdList": ["10.1007/s13402-021-00598-w", "33788151"]}, {"Citation": "Sun CY, Zhang Z, Tao L, Xu FF, Li HY, Zhang HY, et al. . T Cell exhaustion drives osteosarcoma pathogenesis. Ann Transl Med (2021) 9:1447. doi:\u00a010.21037/atm-21-3928", "ArticleIdList": ["10.21037/atm-21-3928", "PMC8506720", "34733999"]}, {"Citation": "Shao XJ, Xiang SF, Chen YQ, Zhang N, Cao J, Zhu H, et al. . Inhibition of M2-like macrophages by all-trans retinoic acid prevents cancer initiation and stemness in osteosarcoma cells. Acta Pharmacol Sin (2019) 40:1343\u201350. doi:\u00a010.1038/s41401-019-0262-4", "ArticleIdList": ["10.1038/s41401-019-0262-4", "PMC6786412", "31296953"]}, {"Citation": "Abbott M, Ustoyev Y. Cancer and the immune system: The history and background of immunotherapy. Semin Oncol Nurs (2019) 35:150923. doi:\u00a010.1016/j.soncn.2019.08.002", "ArticleIdList": ["10.1016/j.soncn.2019.08.002", "31526550"]}, {"Citation": "Liu X, He S, Wu H, Xie H, Zhang T, Deng Z. Blocking the PD-1/PD-L1 axis enhanced cisplatin chemotherapy in osteosarcoma in vitro and in vivo . Environ Health Prev Med (2019) 24:79. doi:\u00a010.1186/s12199-019-0835-3", "ArticleIdList": ["10.1186/s12199-019-0835-3", "PMC6925464", "31864288"]}, {"Citation": "Lussier DM, O\u2019Neill L, Nieves LM, McAfee MS, Holechek SA, Collins AW, et al. . Enhanced T-cell immunity to osteosarcoma through antibody blockade of PD-1/PD-L1 interactions. J Immunother (2015) 38:96\u2013106. doi:\u00a010.1097/CJI.0000000000000065", "ArticleIdList": ["10.1097/CJI.0000000000000065", "PMC6426450", "25751499"]}, {"Citation": "Tawbi HA, Burgess M, Bolejack V, Van Tine BA, Schuetze SM, Hu J, et al. . Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): A multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol (2017) 18:1493\u2013501. doi:\u00a010.1016/S1470-2045(17)30624-1", "ArticleIdList": ["10.1016/S1470-2045(17)30624-1", "PMC7939029", "28988646"]}, {"Citation": "Buddingh EP, Kuijjer ML, Duim RA, B\u00fcrger H, Agelopoulos K, Myklebost O, et al. . Tumor-infiltrating macrophages are associated with metastasis suppression in high-grade osteosarcoma: A rationale for treatment with macrophage activating agents. Clin Cancer Res (2011) 17:2110\u20139. doi:\u00a010.1158/1078-0432.CCR-10-2047", "ArticleIdList": ["10.1158/1078-0432.CCR-10-2047", "21372215"]}, {"Citation": "Chen B, Khodadoust MS, Liu CL, Newman AM, Alizadeh AA. Profiling tumor infiltrating immune cells with CIBERSORT. Methods Mol Biol (2018) 1711:243\u201359. doi:\u00a010.1007/978-1-4939-7493-1_12", "ArticleIdList": ["10.1007/978-1-4939-7493-1_12", "PMC5895181", "29344893"]}, {"Citation": "Park SY. Nomogram: An analogue tool to deliver digital knowledge. J Thorac Cardiovasc Surg (2018) 155:1793. doi:\u00a010.1016/j.jtcvs.2017.12.107", "ArticleIdList": ["10.1016/j.jtcvs.2017.12.107", "29370910"]}, {"Citation": "Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X, et al. . Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med (2018) 24:1550\u20138. doi:\u00a010.1038/s41591-018-0136-1", "ArticleIdList": ["10.1038/s41591-018-0136-1", "PMC6487502", "30127393"]}, {"Citation": "Maeser D, Gruener RF, Huang RS. oncoPredict: An r package for predicting in vivo or cancer patient drug response and biomarkers from cell line screening data. Brief Bioinform (2021) 22:bbab260. doi:\u00a010.1093/bib/bbab260", "ArticleIdList": ["10.1093/bib/bbab260", "PMC8574972", "34260682"]}, {"Citation": "Corre I, Verrecchia F, Crenn V, Redini F, Trichet V. The osteosarcoma microenvironment: A complex but targetable ecosystem. Cells (2020) 9:976. doi:\u00a010.3390/cells9040976", "ArticleIdList": ["10.3390/cells9040976", "PMC7226971", "32326444"]}, {"Citation": "Groisberg R, Hong DS, Behrang A, Hess K, Janku F, Piha-Paul S, et al. . Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials. J Immunother Cancer (2017) 5:100. doi:\u00a010.1186/s40425-017-0301-y", "ArticleIdList": ["10.1186/s40425-017-0301-y", "PMC5735899", "29254498"]}, {"Citation": "Ullenhag GJ, Spendlove I, Watson NF, Kallmeyer C, Pritchard-Jones K, Durrant LG. T-Cell responses in osteosarcoma patients vaccinated with an anti-idiotypic antibody, 105AD7, mimicking CD55. Clin Immunol (2008) 128:148\u201354. doi:\u00a010.1016/j.clim.2008.03.512", "ArticleIdList": ["10.1016/j.clim.2008.03.512", "18508409"]}, {"Citation": "Wculek SK, Cueto FJ, Mujal AM, Melero I, Krummel MF, Sancho D. Dendritic cells in cancer immunology and immunotherapy. Nat Rev Immunol (2020) 20:7\u201324. doi:\u00a010.1038/s41577-019-0210-z", "ArticleIdList": ["10.1038/s41577-019-0210-z", "31467405"]}, {"Citation": "Gardner A, Ruffell B. Dendritic cells and cancer immunity. Trends Immunol (2016) 37:855\u201365. doi:\u00a010.1016/j.it.2016.09.006", "ArticleIdList": ["10.1016/j.it.2016.09.006", "PMC5135568", "27793569"]}, {"Citation": "Boyer DS, Rippmann JF, Ehrlich MS, Bakker RA, Chong V, Nguyen QD. Amine oxidase copper-containing 3 (AOC3) inhibition: A potential novel target for the management of diabetic retinopathy. Int J Retina Vitreous (2021) 7:30. doi:\u00a010.1186/s40942-021-00288-7", "ArticleIdList": ["10.1186/s40942-021-00288-7", "PMC8042903", "33845913"]}, {"Citation": "Ward ST, Weston CJ, Shepherd EL, Hejmadi R, Ismail T, Adams DH. Evaluation of serum and tissue levels of VAP-1 in colorectal cancer. BMC Cancer (2016) 16:154. doi:\u00a010.1186/s12885-016-2183-7", "ArticleIdList": ["10.1186/s12885-016-2183-7", "PMC4766640", "26912327"]}, {"Citation": "Lai YC, Chang SJ, Kostoro J, Kwan AL, Chai CY. Vascular adhesion protein-1 as indicator of breast cancer tumor aggressiveness and invasiveness. APMIS (2018) 126:755\u201361. doi:\u00a010.1111/apm.12885", "ArticleIdList": ["10.1111/apm.12885", "30160019"]}, {"Citation": "Nebenfuehr S, Kollmann K, Sexl V. The role of CDK6 in cancer. Int J Cancer (2020) 147:2988\u201395. doi:\u00a010.1002/ijc.33054", "ArticleIdList": ["10.1002/ijc.33054", "PMC7586846", "32406095"]}, {"Citation": "Ton QV, Leino D, Mowery SA, Bredemeier NO, Lafontant PJ, Lubert A, et al. . Collagen COL22A1 maintains vascular stability and mutations in COL22A1 are potentially associated with intracranial aneurysms. Dis Model Mech (2018) 11:dmm033654. doi:\u00a010.1242/dmm.033654", "ArticleIdList": ["10.1242/dmm.033654", "PMC6307901", "30541770"]}, {"Citation": "Misawa K, Kanazawa T, Imai A, Endo S, Mochizuki D, Fukushima H, et al. . Prognostic value of type XXII and XXIV collagen mRNA expression in head and neck cancer patients. Mol Clin Oncol (2014) 2:285\u201391. doi:\u00a010.3892/mco.2013.233", "ArticleIdList": ["10.3892/mco.2013.233", "PMC3917764", "24649348"]}, {"Citation": "Seto M, Weiner RL, Dumitrescu L, Mahoney ER, Hansen SL, Janve V, et al. . RNASE6 is a novel modifier of APOE-\u03f54 effects on cognition. Neurobiol Aging (2022) 118:66\u201376. doi:\u00a010.1016/j.neurobiolaging.2022.06.011", "ArticleIdList": ["10.1016/j.neurobiolaging.2022.06.011", "35896049"]}, {"Citation": "Lichtenstern CR, Ngu RK, Shalapour S, Karin M. Immunotherapy, inflammation and colorectal cancer. Cells (2020) 9:618. doi:\u00a010.3390/cells9030618", "ArticleIdList": ["10.3390/cells9030618", "PMC7140520", "32143413"]}, {"Citation": "Jiang M, Jia K, Wang L, Li W, Chen B, Liu Y, et al. . Alterations of DNA damage response pathway: Biomarker and therapeutic strategy for cancer immunotherapy. Acta Pharm Sin B (2021) 11:2983\u201394. doi:\u00a010.1016/j.apsb.2021.01.003", "ArticleIdList": ["10.1016/j.apsb.2021.01.003", "PMC8546664", "34729299"]}, {"Citation": "Lin A, Zhang J, Luo P. Crosstalk between the MSI status and tumor microenvironment in colorectal cancer. Front Immunol (2020) 11:2039. doi:\u00a010.3389/fimmu.2020.02039", "ArticleIdList": ["10.3389/fimmu.2020.02039", "PMC7435056", "32903444"]}, {"Citation": "Miwa S, Nishida H, Tanzawa Y, Takeuchi A, Hayashi K, Yamamoto N, et al. . Phase 1/2 study of immunotherapy with dendritic cells pulsed with autologous tumor lysate in patients with refractory bone and soft tissue sarcoma. Cancer (2017) 123:1576\u201384. doi:\u00a010.1002/cncr.30606", "ArticleIdList": ["10.1002/cncr.30606", "28241093"]}, {"Citation": "Krishnadas DK, Shusterman S, Bai F, Diller L, Sullivan JE, Cheerva AC, et al. . A phase I trial combining decitabine/dendritic cell vaccine targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma. Cancer Immunol Immunother (2015) 64:1251\u201360. doi:\u00a010.1007/s00262-015-1731-3", "ArticleIdList": ["10.1007/s00262-015-1731-3", "26105625"]}], "ReferenceList": []}], "History": [{"Year": "2022", "Month": "8", "Day": "11"}, {"Year": "2022", "Month": "8", "Day": "23"}, {"Year": "2022", "Month": "10", "Day": "3", "Hour": "5", "Minute": "19"}, {"Year": "2022", "Month": "10", "Day": "4", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "10", "Day": "5", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "1", "Day": "1"}], "PublicationStatus": "epublish", "ArticleIdList": ["36189307", "PMC9515362", "10.3389/fimmu.2022.1017120"]}}], "PubmedBookArticle": []}